Quantcast
Last updated on April 23, 2014 at 13:57 EDT

Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus

December 23, 2013

TSX Exchange Symbol: RVX

CALGARY, Dec. 23, 2013 /PRNewswire/ – Resverlogix Corp. (TSX:RVX) today
announced that it has completed enrollment of its exploratory Phase 2
clinical trial in patients with pre-diabetes mellitus to examine the
effects of RVX-208 and ApoA-I production on glucose metabolism.
Approximately 80% of patients with diabetes die from cardiovascular
disease (CVD), most notably myocardial infarct and stroke. The trial is
conducted in collaboration with Baker IDI Heart & Diabetes Institute in
Melbourne, Australia. This trial will examine insulin secretion,
insulin sensitivity and other parameters of importance in diabetes and
cardiovascular disease. A total of twenty patients have been enrolled
in Australia, with data expected on time in mid-2014.

The foundation of this trial builds upon the known actions of RVX-208
and the knowledge that this compound triggers a key epigenetic pathway
resulting in enhanced ApoA-I protein production to raise the body’s
level of functional HDL particles. The effect of newly created
ApoA-I/HDL may help to improve glucose control through effects on not
only pancreatic cells that make and secrete insulin but also muscle,
the major site of glucose utilization in the body. These actions have
the potential to improve on important risk factors for cardiovascular
disease associated with the diabetic state.

“The prevalence of diabetes mellitus is rising at epidemic rates around
the world adding to the incidence of cardiovascular disease. The
results from our current study will shed important light on the
potential of RVX-208, the first compound affecting epigenetics to be
tested in potentially reducing CVD-risk in patients with diabetes
mellitus.” said Dr. Norman Wong, Chief Scientific Officer of
Resverlogix.

Principal Investigator, Professor Bronwyn Kingwell said, “This work
builds on a strong evidence base regarding novel actions of HDL on
glucose control. If positive, these studies will support therapeutic
approaches to raise levels of circulating HDL to help reduce CVD-risk
and further improve management of Type II Diabetes and its
complications.”

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET
bromodomains. RVX-208 functions by removing atherosclerotic plaque via
reverse cholesterol transport (RCT), the natural process through which
atherosclerotic plaque is transported out of the arteries and removed
from the body by the liver. RVX-208 increases production of
Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for
RCT. These newly produced, functional HDL particles are flat and empty
and can efficiently remove plaque and stabilize or reverse
atherosclerotic disease. Analysis of recent clinical trials data showed
that RVX-208 significantly reduces coronary atherosclerosis and major
adverse cardiac events in patients with CVD who have a low level of HDL
and elevated CRP, a population with unmet medical need. ApoA-I may also
exert beneficial effects in Alzheimer’s disease and Diabetes Mellitus.

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company
developing compounds involving ApoA-I production. RVX-208 is a
first-in-class small molecule in development for the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s
disease. RVX-208 is the first BET bromodomain inhibitor in clinical
trials. Resverlogix’s common shares trade on the Toronto Stock Exchange
(TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

Resverlogix IR App

This app gives Resverlogix investors mobile access to the latest stock
data, news, and SEC Filings. It also provides proprietary company
content including presentations, conference calls, videos, fact sheets,
annual reports and other qualitative company information. Investors are
able to receive ‘push’ notifications when new content is added to the
IR App such as add events to calendars, share content and as well as
download files for offline viewing.

To download the Resverlogix IR App, please visit your app store.

Apple Products (iPhone, iPad, and iPod’s)https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=730718904&mt=8

Android Products (Google Play, Tablets and Smartphones)https://play.google.com/store/apps/details?id=com.theirapp.resverlogix

This news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are not
based on historical fact, including without limitation statements
containing the words “believes”, “anticipates”, “plans”, “intends”,
“will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer’s
disease. Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and risk
factors including those discussed in our Annual Information Form and
most recent MD&A which are incorporated herein by reference and are
available through SEDAR at www.sedar.com. The forward-looking
statements contained in this news release are expressly qualified by
this cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.


    Company Contacts:

    Donald J. McCaffrey                                              Kenneth Lebioda

    President and CEO                                                SVP Business & Corporate Development

    Resverlogix Corp.                                                Resverlogix Corp.

    Phone: 403-254-9252                                              Phone: 403-254-9252

    Email:                                                           Email:
    don@resverlogix.com     ken@resverlogix.com

SOURCE Resverlogix Corp.


Source: PR Newswire